Alzheimer'sREMIND-EUNCT07708675
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EU
A study testing Symani Surgical System in people with Alzheimer's, run by MMI (Medical Microinstruments, Inc.).
Trial summary
The objective of this study is to evaluate the safety and feasibility of the Symani System and microsurgical techniques in the deep Cervical Lymph Node (dCLN) region in patients with confirmed Alzheimer's disease. Read more about this study
- Who is it for?
- Ages 50 to 80 years
- Conditions the study is for
- Alzheimer's
- What is being tested?
- Symani Surgical System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Mar 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 50 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Preoperative Inclusion Criteria:
- Patient aged 50 to < 80 years
- Patient has confirmed highly probable or probable Alzheimer's disease according to the International Working Group (IWG) Patient and has a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria
- Patient has an MMSE score≥ 18
- Investigator deems the candidate acceptable for lymphatic surgery with a robotic-assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)
- Patients who are of childbearing potential must agree to use a medically acceptable form of contraception.
- Patient or their legally authorized representative agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure
Intraoperative Inclusion Criteria:
- Intraoperative imaging confirms lymphatic nodes/vessels amenable to reconstruction
Preoperative Exclusion Criteria:
- Patient (or their legally authorized representative) is unwilling to provide informed consent
- Patient has suspected dementia of other type, e.g., Lewy body, frontotemporal disorder, vascular, etc.
- History of head and neck radiation exposure
- Patient with severe kidney disease (GFR <30 mL/min/1.73m2)
- Patient with acute kidney injury
- Active systemic infection under treatment with intravenous antibiotics
- Patient has a modified Rankin Score (mRS) of >4
- Documented history of clinically significant diagnosis of cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, untreated sleep apnea, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion
- Known history of significant bleeding, coagulopathy, or Von Willebrand's disease
- Patient with an active cancer diagnosis and/or currently receiving treatment for cancer or has received treatment within the past 6 months
- Patient is currently receiving treatment or has been treated with anti-amyloid-beta monoclonal antibody therapy within the past 6 months
- Patient has contraindication for MRI
- Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or study outcomes
- Patient is ineligible to participate for other reasons in the judgment of the investigator
Intraoperative Exclusion Criteria:
- Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - A European, Prospective, Multi-Center, Open Label Study in Alzheimer's Patients
The objective of this study is to evaluate the safety and feasibility of the Symani System and microsurgical techniques in the deep Cervical Lymph Node (dCLN) region in patients with confirmed Alzheimer's disease.
Read the detailed description
A prospective, multicenter open label study, designed to evaluate the Symani System's safety and feasibility for performing microsurgical techniques in the dCLNs to improve clearance of neurotoxins, such as amyloid-beta and phosphorylated tau, in patients with confirmed highly probable or probable Alzheimer's Disease, according to the International Working Group (IWG) and a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria.
- Conditions
- Alzheimer's
- Being tested
- Symani Surgical System
- Keywords
- Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders, Alzheimer Disease
- Medical subject headings
- Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Symani Surgical SystemDevice
Use of Symani Surgical System for performing microsurgical techniques in the deep cervical lymph nodes.
| Study group | Role | What they receive |
|---|---|---|
| Alzheimer's Disease | Experimental | Patient with confirmed mild to moderate Alzheimer's Disease according to the International Working Group (IWG) and a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria. Receives: Device: Symani Surgical System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Device-related serious adverse events at 30-days
All intraoperative and postoperative device-related serious adverse events (SAEs) will be captured from the start of the index procedure through 30 days post-index procedure for each participant. The device-related SAE rate will be reported at 30 days post-index procedure for all evaluable participants.
Measured: The duration of the participants' index procedure through 30-days post index procedure.
Secondary outcomes (11)
Rate of Serious Adverse Events (SAEs) through 12 months
All intraoperative and postoperative SAEs, regardless of device relatedness, will be captured from the start of the index procedure through 12 months post-index procedure for each participant. The freedom from SAE rate will be reported through 12 months post-index procedure for all evaluable participants.
Measured: The duration of the participants' index procedure through 12-months post index procedure.
Rate of Adverse Events (AEs) at 30 days
All intraoperative and postoperative AEs, regardless of seriousness or device relatedness, will be captured from the start of the index procedure through 30 days post-index procedure for each participant. The freedom from AE rate will be reported at 30 days post-index procedure for all evaluable participants.
Measured: The duration of the participants' index procedure through 30-days post index procedure.
Incidence of Post Operative Delirium
Post Operative Delirium occurrence shall be collected from the end of the indexing procedure through discharge, as an AE.
Measured: From Day 0 visit through 12-24 hours prior to discharge.
Change in Amyloid PET Centiloid Value at 6 and 12- Months
The centiloid (CL) value of an amyloid positron emission tomography (PET) imaging test will be performed at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit for this comparison.
Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Change in Plasma Biomarkers at 3, 6, and 12 Months: amyloidβ-42 and 40, amyloidβ-42/40 ratio, ptau-217, NfL and GFAP
Blood panel testing for amyloidβ-42 and 40, amyloidβ-42/40 ratio, ptau-217, neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) will be taken at the patient's pre-procedure visit and at the 3, 6, and 12-month follow-up visits.
Measured: The duration of the participants' pre-procedure visit through 3, 6, and 12-months post index procedure.
Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score at 6 and 12 Months
CDR-SB will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit. The CDR-SB scores can take a value between 0 and 18.
Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Domains at 6 and 12 Months
Each of the 6 domains of the CDR-SB -- memory, orientation, judgement, problem solving, community affairs, home and hobbies, and personal care -- will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit.
Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Alzheimer's Disease Assessment Scvale-Cognitive (ADAS-Cog14) at 6 and 12 months
ADAS-Cog14 will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit. The scores range from 0 to 70.
Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Mini-Mental State Examination (MMSE) at 6 and 12 Months
MMSE will be evaluated at the patient's pre-procedure visit and at the 6 and 12-month follow-up visit. The scores range from 0 to 30.
Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Activities of Daily Living (ADSC-ADL) at 6 and 12-Months
ADSC-ADL will be evaluated at the patient's pre-procedure visit and at the 6-month follow-up visit. The scores range from 0 to 78. Questions are asked of the patient's caregiver/family member to best gauge the patient's ability to complete basic and instrumental activities of daily living
Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Change in Zarit Burden Interview (ZBI) at 6 and 12 months
The ZBI shall be administered at the patient's pre-procedural visit and at the 6 and 12-month visits. This 22-item scale is administered to the patient's caregiver/family member to assess the caregiver's burden.
Measured: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Apr 2028 (estimated)
- Study completion1 Mar 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer'sStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- MMI (Medical Microinstruments, Inc.)
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07708675
- Sponsor's protocol ID
- CDC-00176
- Acronym
- REMIND-EU
- Status last verified
- Jul 2026
- First submitted
- 10 Jul 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - A European, Prospective, Multi-Center, Open Label Study in Alzheimer's Patients
- ClinicalTrials.gov ID
- NCT07708675
- Acronym / sponsor ID
- REMIND-EU / CDC-00176
- Conditions
- Alzheimer's
- Keywords
- Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- MMI (Medical Microinstruments, Inc.)Industry (pharma, biotech, devices)
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Apr 2028 (estimated)
- Study completion
- 1 Mar 2029 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this study is to evaluate the safety and feasibility of the Symani System and microsurgical techniques in the deep Cervical Lymph Node (dCLN) region in patients with confirmed Alzheimer's disease.
Detailed description
A prospective, multicenter open label study, designed to evaluate the Symani System's safety and feasibility for performing microsurgical techniques in the dCLNs to improve clearance of neurotoxins, such as amyloid-beta and phosphorylated tau, in patients with confirmed highly probable or probable Alzheimer's Disease, according to the International Working Group (IWG) and a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Alzheimer's Disease | Experimental | Device: Symani Surgical SystemPatient with confirmed mild to moderate Alzheimer's Disease according to the International Working Group (IWG) and a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria. |
Who may qualify
- Ages
- 50 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Symani Surgical SystemUse of Symani Surgical System for performing microsurgical techniques in the deep cervical lymph nodes. | Device | Alzheimer's Disease |
Primary outcome
Device-related serious adverse events at 30-days
Time frame: The duration of the participants' index procedure through 30-days post index procedure.
All intraoperative and postoperative device-related serious adverse events (SAEs) will be captured from the start of the index procedure through 30 days post-index procedure for each participant. The device-related SAE rate will be reported at 30 days post-index procedure for all evaluable participants.
11 secondary outcomes
Rate of Serious Adverse Events (SAEs) through 12 months
Time frame: The duration of the participants' index procedure through 12-months post index procedure.
Rate of Adverse Events (AEs) at 30 days
Time frame: The duration of the participants' index procedure through 30-days post index procedure.
Incidence of Post Operative Delirium
Time frame: From Day 0 visit through 12-24 hours prior to discharge.
Change in Amyloid PET Centiloid Value at 6 and 12- Months
Time frame: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Change in Plasma Biomarkers at 3, 6, and 12 Months: amyloidβ-42 and 40, amyloidβ-42/40 ratio, ptau-217, NfL and GFAP
Time frame: The duration of the participants' pre-procedure visit through 3, 6, and 12-months post index procedure.
Change in Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Score at 6 and 12 Months
Time frame: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Clinical Dementia Rating Scale-Sum of Boxes (CDR-SB) Domains at 6 and 12 Months
Time frame: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Alzheimer's Disease Assessment Scvale-Cognitive (ADAS-Cog14) at 6 and 12 months
Time frame: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Mini-Mental State Examination (MMSE) at 6 and 12 Months
Time frame: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Activities of Daily Living (ADSC-ADL) at 6 and 12-Months
Time frame: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Change in Zarit Burden Interview (ZBI) at 6 and 12 months
Time frame: The duration of the participants' pre-procedure visit through 6 and 12-months post index procedure.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
Related trials for Alzheimer's
Not yet recruiting
Virtual Reality to Advance Dementia Care and Quality of Life
Dementia, Agitation
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
VICA: A Virtual Care Assistant for Dementia Caregivers
Alzheimer Dementia (AD), Caregiver Burden of People With Dementia
RecruitingPhase 2
Alzheimer's Tau Platform: Master Protocol
Preclinical Alzheimer's Disease, Alzheimer Disease
Enrolling by invitationPhase 2
Alzheimer's Tau Platform: Regimen A - AADvac1
Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A study testing Symani Surgical System in people with Alzheimer's, run by MMI (Medical Microinstruments, Inc.).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Clinical Operations (8336646276 ext. 5, clinical.ops@mmimicro.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Device-related serious adverse events at 30-days (time frame: The duration of the participants' index procedure through 30-days post index procedure.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.